There are approximately 10 million women who underwent breast augmentation with breast implants in the whole world. Currently, breast augmentation is the number 1 cosmetic procedure performed in the United States with approximately 500,000 implants placed every year.
Breast implant-associated anaplastic large cell lymphoma (ALCL) is a dinstinctive type of T-cell lymphoma that occurs after breast augmentation or enlargement. This occurs around the breast implants itself. Fortunately, this is a rare condition with approximately 258 cases that has been documented since 1997 (as of September 2015.)
Clinical Findings and Symptoms of Patients who may potentially have ALCL:
- Persistent Seroma
- Seroma associated with breast pain or swelling
- Occurs an average of 9 years after breast augmentation
- All reported cases of breast implant-associated ALCL have involved textured breast implants
What are your risks for developing ALCL (Anaplastic Large Cell Lymphoma)?
- incidence varies from 0.1 and 0.3 per 100,000 women with breast implants per year.
- One in 100 million women per year in the general population (based on the data from the Surveillance, Epidemiology and End Results Program of the National Cancer Institute.)
- Lifetime prevalence was 33 per 1 million women with a textured breast implant or 1 per 30,000 women with a textured breast implant.
I recommend discussing your risks for development of ALCL with your plastic surgeon prior to having breast augmentation.
Doren, et al. US Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plastic and Reconstructive Surgery. Volume 139 Number 5May 2017 pp104-1049
Emmanuel De La Cruz MD, PLLC
Plastic & Reconstructive Surgeon (Houston, TX)